Thursday, February 14, 2013

Merck Pays $688M To Settle Suits Over Enhance Trial

On the eve of a widely anticipated courtroom battle, Merck has agreed to settle shareholder lawsuits over the highly controversial Enhance clinical trial for the Vytorin cholesterol pill. The latest deal actually resolves two separate lawsuits in which the drugmaker has agreed to make a total payment of $688 million, which was described as one of the 25 largest securities class action settlements ever by the lawyers who represented Merck shareholders.

More here

No comments: